P4HTM

Across TCGA pan-cancer cohorts, P4HTM Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated P4HTM data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher P4HTM Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated P4HTM expression acts as an unfavorable survival marker.

OV, STAD, and CESC are the cancer types where P4HTM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.251	0.542	.005	18	view →
STAD	OS	Median	All	0.226	0.734	<.001	18	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
SKCM	DFS	Median	All	0.192	0.757	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

P4HTM–OV (DFS)

Open the OV breakdown →